An evaluation of apremilast for the treatment of adult patients with oral ulcers associated with Behçet’s syndrome

References

• Mendoza-Pinto C, Garcia-Carrasco M, Jimenez-Hernandez M, et al. Etiopathogenesis of Behcet’s disease. Autoimmun Rev. 2010;9(4):241–245
   PubMed Web of Science ®Google Scholar
• Alpsoy E, Zouboulis CC, Ehrlich GE. Mucocutaneous Lesions of Behcet’s Disease. Yonsei Med J. 2007;48(4):573–585
   PubMed Web of Science ®Google Scholar
• Alpsoy E. Behcet’s disease: a comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. J Dermatol. 2016;43(6):620–632.
   PubMed Web of Science ®Google Scholar
• Keogan MT. Clinical Immunology Review Series: an approach to the patient with recurrent orogenital ulceration, including Behcet’s syndrome. Clin Exp Immunol. 2009;156(1):1–11.
   PubMed Web of Science ®Google Scholar
• Ideguchi H, Suda A, Takeno M, et al. Behcet disease: evolution of clinical manifestations. Medicine (Baltimore). 2011;90(2):125–132.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020–1026
   Google Scholar
• Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583–1590.
   PubMed Web of Science ®Google Scholar
• Keating GM. Apremilast: a Review in Psoriasis and Psoriatic Arthritis. Drugs. 2017;77(4):459–472.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Melikoglu M, Tunc R, et al., Apremilast for Behcet’s syndrome–a phase 2, placebo-controlled study. N Engl J Med. 2015.372(16):1510–1518.
   Google Scholar
• Hatemi G, Mahr A, Ishigatsubo Y, et al., Trial of Apremilast for Oral Ulcers in Behcet’s Syndrome. N Engl J Med. 381(20): 1918–1928. 2019.
   Google Scholar
• Perez-Aso M, Montesinos MC, Mediero A, et al. Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. Arthritis Res Ther. 2015;17(1):249
   Google Scholar
• Schafer PH, Chen P, Fang L, et al. The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1). J Immunol Res. 2015;2015:906349
   PubMed Web of Science ®Google Scholar
• Hatemi G, Yazici Y. Apremilast for the treatment of Behcet’s syndrome. Expert Opin Orphan Drugs. 2017;5(8):677–681
   Web of Science ®Google Scholar
• O’Neill TW, Rigby AS, Silman A, et al. Validation of the International Study Group criteria for Behçet’s disease. Br J Rheumatol. 1994;33(2):115–117
   Google Scholar
• Kim DY, Choi MJ, Kim HY, et al. Development and validation of an electronic medical record-based disease activity index for Behçet’s disease. Clin Exp Rheumatol. 2014;32(4):S40–4
   PubMed Web of Science ®Google Scholar
• Yilmaz S, Simsek I, Cinar M, et al. Patient-driven assessment of disease activity in Behçet’s syndrome: cross-cultural adaptation, reliability and validity of the Turkish version of the Behçet’s Syndrome Activity Score. Clin Exp Rheumatol. 2013;31(3):77–83
   PubMed Web of Science ®Google Scholar
• Gilworth G, Chamberlain MA, Bhakta B, et al. Development of the BD-QoL: a quality of life measure specific to Behçet’s disease. J Rheumatol. 2004;31(5):931–937
   PubMed Web of Science ®Google Scholar
• De Luca G, Cariddi A, Campochiaro C, et al. Efficacy and safety of apremilast for Behcet’s syndrome: a real-life single-centre Italian experience. Rheumatology (Oxford). 2020;59(1):171–175
   PubMed Web of Science ®Google Scholar
• Atienza-Mateo B, Martín-Varillas J, Graña J, Espinosa G , et al. Spanish Collaborative Group of Refractory Behçet’s Disease. Apremilast in refractory orogenital ulcers and other manifestations of Behçet’s disease. A national multicentre study of 51 cases in clinical practice. Clin Exp Rheumatol. 2020;38(5):69–75.
   Google Scholar
• Vieira M, Buffier S, Vautier M, et al. Apremilast in Refractory Behcet’s Syndrome: a Multicenter Observational Study. Front Immunol. 2020;11:626792.
   Google Scholar
• Hirahara L, Kirino Y, Soejima Y, et al. Efficacy and safety of apremilast for 3 months in Behcet’s disease: a prospective observational study. Mod Rheumatol 2020 1–6 https://doi.org/10.1080/14397595.2020.1830504
   Google Scholar
• Lopalco G, Venerito V, Leccese P, et al. Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behcet’s disease. Ann Rheum Dis. 2019;78(12):1736–1737
   PubMed Web of Science ®Google Scholar
• Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75(6):1065–1073
   PubMed Web of Science ®Google Scholar
• Vieira M, Vautier M, Charlotte F, et al. Mycobacterium bovis infection under apremilast in Behçet’s syndrome. Rheumatology (Oxford). 2021. https://doi.org/10.1093/rheumatology/keab199
   Google Scholar
• Magro C, Crowson A. Cutaneous manifestations of Behçet’s disease. Int J Dermatol. 1995;34(3):159–165
   PubMed Web of Science ®Google Scholar
• Hatemi G, Christensen R, Bang D, et al. update of the EULAR recommendations for the management of Behcet’s syndrome. Ann Rheum Dis. 2018;77(6):808–818
   PubMed Web of Science ®Google Scholar
• Schafer PH, Truzzi F, Parton A, et al. Phosphodiesterase 4 in inflammatory diseases: effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex. Cell Signal. 2016;28(7):753–763
   PubMed Web of Science ®Google Scholar
• Vossen A, MBA VD, van der Zee HH, et al. Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial. J Am Acad Dermatol. 2019;80(1):80–88
   Google Scholar
• Chen T, Levitt J, Geller L. Apremilast for treatment of recurrent erythema multiforme. Dermatol Online J. 2017;23(1):23.
   Google Scholar
• Alibaz-Oner F, Mumcu G, Kubilay Z, et al. Unmet need in Behcet’s disease: most patients in routine follow-up continue to have oral ulcers. Clin Rheumatol. 2014;33(12):1773–1776
   Google Scholar
• Ozguler Y, Merkel PA, Gurcan M, et al. Patients’ experiences with Behçet’s syndrome: structured interviews among patients with different types of organ involvement. Clin Exp Rheumatol. 2019;37(6):28–34
   PubMed Web of Science ®Google Scholar